SOMA Research

What Is GHK-Cu? A Research Guide to the Copper Tripeptide

GHK-Cu is a copper-binding tripeptide: three amino acids coordinated to a single copper(II) ion. It is the smallest compound in the SOMA catalogue and the only one whose defining property is a metal complex rather than the peptide sequence alone. That distinction changes how it is characterised, how it is stored, and what can go wrong with it. This guide covers the chemistry, the published research context, and the handling consequences.

SOMA Research supplies GHK-Cu for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.

What GHK-Cu is

The peptide is glycyl-L-histidyl-L-lysine — GHK — a naturally occurring tripeptide first isolated from human plasma. In its active form it is complexed with copper(II), giving copper tripeptide-1. Published identifiers:

  • Peptide sequence: Gly-His-Lys (GHK)
  • CAS number (GHK-Cu complex): 89030-95-5
  • CAS number (GHK free peptide): 49557-75-7
  • Molecular formula (complex): C14H24CuN6O4
  • Molecular weight: approximately 403.9 g/mol for the complex, 340.4 g/mol for the free tripeptide
  • Appearance: blue to blue-violet powder

The colour is not cosmetic — it is the analytical tell. Copper(II) complexes absorb in the visible range, and the characteristic blue of GHK-Cu comes from d-d transitions in the coordinated copper centre. A GHK-Cu preparation that is white or off-white is either the uncomplexed peptide or a preparation in which the copper is not coordinated as intended. This is the rare case where an initial visual inspection carries real information.

How the copper is bound

The coordination chemistry is the reason the sequence is what it is. The histidine imidazole nitrogen, the N-terminal amine and the deprotonated backbone amide nitrogen together form a square-planar arrangement around the copper(II) ion, with the lysine side chain extending away from the coordination sphere. It is a high-affinity, well-characterised binding geometry, and it is specific to this sequence — the tripeptide is not simply a convenient copper carrier but a defined complex.

Two practical consequences follow. First, pH matters: the backbone amide deprotonation required for the complex is pH-dependent, so the complex is not equally stable across all buffer conditions. Second, chelating agents compete. EDTA and similar chelators will strip copper from the complex, so a buffer containing a chelator will quietly convert GHK-Cu into free GHK plus a copper-EDTA complex — a different experiment than the one intended.

Published research context

GHK was identified in human plasma, and a recurring observation in the literature is that its plasma concentration declines with age. The published preclinical work falls into several threads:

  • Extracellular matrix studies. Cell-culture work examining collagen and glycosaminoglycan synthesis in fibroblast models.
  • Metalloproteinase modulation. Reported effects on matrix metalloproteinases and their tissue inhibitors in culture.
  • Gene expression profiling. Microarray and transcriptomic studies reporting broad changes in expression patterns in cultured human cells.
  • Copper transport. Work treating the complex as a physiological copper-delivery species rather than as a peptide acting alone.

The gene-expression literature is the thread most often over-interpreted commercially. Reporting that a compound changes the expression of a large number of genes in a cell-culture model is a description of a transcriptional response, not evidence of a clinical outcome. As with every compound in this catalogue, there is no approved human indication and no completed body of peer-reviewed human efficacy data to draw on.

Characterising a GHK-Cu batch

GHK-Cu needs the standard two measurements and benefits from a third:

  • HPLC purity. Reversed-phase separation of the target from synthesis-related impurities. Note that chromatography of a metal complex can behave differently from that of a free peptide, and some methods analyse the peptide after deliberate decomplexation.
  • Mass spectrometry. Identity confirmation. The observed mass depends on whether the free peptide (~340.4) or the copper complex (~403.9) is being measured, and a CoA should make clear which. Copper’s two stable isotopes, 63Cu and 65Cu, produce a recognisable isotope pattern in the complex — useful confirmation that the metal is present.
  • Copper content. A direct elemental measurement is the most unambiguous evidence that the complex is stoichiometric rather than partially formed.

SOMA lots are tested by third-party laboratories using HPLC and mass spectrometry, with measured figures published per lot in our CoA library. Our guide on reading a Certificate of Analysis explains how to interpret those fields and which combinations should prompt a question.

Handling and storage

GHK-Cu is more demanding than a plain peptide, for reasons that trace back to the copper:

  • Light. Protect from light at every stage. Copper complexes are photosensitive and the compound is supplied in opaque or amber containers for that reason.
  • Lyophilised powder: store at -20°C.
  • Reconstituted stock: 2–8°C, used within approximately 30 days, aliquoted to avoid freeze-thaw cycles.
  • Avoid chelators. No EDTA, EGTA or citrate in buffers unless the experiment is specifically about decomplexation.
  • Watch the pH. Strongly acidic conditions will protonate the coordinating nitrogens and destabilise the complex.
  • Avoid reducing agents. Reductants capable of converting Cu(II) to Cu(I) will change the species in solution.
  • Colour as a check. Loss of the blue colour in a stored solution is a visible indication that the complex has not survived.

General reconstitution procedure and concentration arithmetic are covered in our reconstitution guide; the chelator and light constraints above are specific to this compound and apply on top of it.

Getting the concentration right

Concentration errors with GHK-Cu are more common than with ordinary peptides, and they come from three places that compound one another.

Which molecular weight you used. 403.9 g/mol for the complex against 340.4 for the free tripeptide is an 18% difference. Using the free-peptide mass to prepare a solution of the complex produces a stock that is 18% off before anything else happens.

Whether the material is a salt. As with other peptides, research-grade material may be supplied as a salt, and the counter-ion contributes to the weighed mass without contributing peptide. The CoA peptide-content figure is what resolves this, and it is a separate number from the HPLC purity figure.

Whether the complex is stoichiometric. A preparation that is 1:1 peptide to copper behaves as intended. One in which some fraction of the peptide is uncomplexed is a mixture of two species with different properties, and an HPLC purity figure alone will not necessarily reveal it. This is why an elemental copper determination is worth asking for on a complex, even though it is not standard on a peptide CoA.

Each of these is individually modest and they multiply. Two of them together can put a nominal 1 mM stock meaningfully outside its stated concentration, which matters for any dose-response work where the curve is the result.

Quality failures specific to this compound

  • Pale or white powder. The complex should be blue to blue-violet. A pale preparation suggests incomplete complexation or a predominantly free-peptide product.
  • Green discolouration. Can indicate copper species other than the intended complex.
  • Precipitate on reconstitution. Copper complexes can precipitate at unfavourable pH or in phosphate-containing buffers; check the solvent before concluding the material is at fault.
  • Colour loss on storage. The clearest sign that a stock has degraded, and one no other compound in the catalogue gives you for free.
  • A CoA that does not say which species was measured. Free peptide and complex give different masses; a document that reports a mass without naming the species leaves the central question open.

GHK-Cu and GHK

Both forms appear in the literature and they are not interchangeable. The free tripeptide is a peptide; the complex is a copper delivery species with a defined coordination geometry. Studies attributing an effect to “GHK” may be using either, and the distinction is frequently blurred in secondary sources. When comparing published results, check which species the paper actually used — and when ordering, check which one the CoA describes, since the molecular weights differ by the mass of the copper ion and any molarity calculation will inherit that difference.

Research use only

Research-grade GHK-Cu is supplied for laboratory use by qualified researchers and institutions. It is not manufactured to pharmaceutical standards, has not been approved by the FDA for any use, and must not be used in or on humans or animals. Nothing in this guide is medical advice or a representation that the compound is safe or effective for any purpose.